MedTrace Logo

Study of Remimazolam for Cataract Surgery

NCT07325227 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-29

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if the use of the sedative remimazolam improves the safety of patients having cataract surgery by decreasing the number of sedation-related complications during and after surgery, and shortening post-surgical cognitive recovery time.

Conditions

  • Cataract Surgery Anesthesia

Interventions

DRUG

Arm 1 Cataract Surgery performed with remimazolam as sedative

Sedation will be remimazolam in one eye and the standard of care in the other eye.

DRUG

Arm 2 Cataract Surgery performed with standard of care sedative

Standard of care sedative will be used during surgery.

Sponsors & Collaborators

  • Eagle Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Massachusetts Eye and Ear Infirmary

    collaborator OTHER

  • Fred E, Shapiro

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-28
Primary Completion
2028-01-01
Completion
2028-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07325227 on ClinicalTrials.gov